Efficacy of antibiotic prophylaxis against ventilator-associated pneumonia

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Neurology

Background:

• Ventilator-associated pneumonia (VAP) poses a significant challenge in intensive care units.
• Neurologic patients with severe stroke are particularly vulnerable to VAP.
• Effective preventive strategies for VAP are crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of prophylactic piperacillin-tazobactam in preventing VAP among neurologic patients with acute stroke.
• To compare the incidence of early-onset and late-onset VAP between patients receiving prophylactic antibiotics and those in the control group.

Main Methods:

• A double-blind clinical trial involving 84 neurologic patients with a Glasgow Coma Score ≤8.
• Patients received either piperacillin-tazobactam or a placebo at the time of intubation and 12 hours later.
• Incidence of early-onset (≤4 days) and late-onset VAP was recorded and compared between groups.

Main Results:

• The incidence of early-onset VAP was significantly lower in the piperacillin-tazobactam group (9.2 episodes per 1000 days) compared to the control group (26.9 episodes per 1000 days).
• The odds ratio for early-onset VAP was 0.217 (95% CI: 0.056-0.085; P = 0.028).
• No significant difference in the incidence of late-onset VAP was observed between the groups.

Conclusions:

• Prophylactic administration of piperacillin-tazobactam may be effective in reducing early-onset VAP in mechanically ventilated neurologic patients.
• The prophylactic antibiotic strategy does not appear to confer protection against late-onset VAP.
• Further research is warranted to optimize VAP prevention strategies in high-risk patient populations.